Literature DB >> 24000938

Pravastatin improves the impaired nitric oxide-mediated neurogenic and endothelium-dependent relaxation of corpus cavernosum in aged rats.

Selvinaz Dalaklioglu1, Pinar Sahin, Arda Tasatargil, Ciler Celik-Ozenci.   

Abstract

AIM: The aim of this study was to investigate the effect of pravastatin treatment on diminished corpus cavernosum (CC) function associated with aging.
METHODS: Male rats were divided into three groups as adult rats (12-14 weeks old), aged rats (72-80 weeks old) and aged rats given 10 mg/kg/d pravastatin in drinking water for six weeks. Blood pressure was measured by tail-cuff method. Total cholesterol, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, triglycerides and testosterone levels were estimated in blood. Changes in expression levels of endothelial nitric oxide synthase (eNOS), phosphorylated eNOS (p-eNOS) (Ser-1177), neuronal nitric oxide synthase (nNOS), NADPH oxidase subunit gp91(phox), Rho A and Rho kinase (ROCK2) in CC were assessed by immunohistochemistry. Nitric oxide (NO)-mediated endothelium-dependent and neurogenic CC relaxation were evaluated by acetylcholine (ACh, 0.1 nM-100 µM) and electrical field stimulation (EFS; 30 V, 5 ms, 2-32 Hz), respectively.
RESULTS: In aged rats, NO-mediated, both endothelium-dependent and neurogenic CC relaxation, were significantly impaired as compared to adult rats. Besides, eNOS, p-eNOS and nNOS expressions decreased significantly in CC from aged rats, while gp91(phox), RhoA and ROCK2 expressions increased significantly. The diminished relaxation in response to ACh or EFS as well as the changes in expression of these proteins in aged rats were significantly improved by pravastatin treatment.
CONCLUSION: Pravastatin improves NO-mediated CC relaxations of aged rats probably by inhibiting NADPH oxidase/Rho kinase pathways, and this effect does not seem to be associated with lipid lowering effect of this drug.

Entities:  

Keywords:  Aging; NADPH oxidase; corpus cavernosum; nitric oxide; pravastatin; rho kinase

Mesh:

Substances:

Year:  2013        PMID: 24000938     DOI: 10.3109/13685538.2013.832194

Source DB:  PubMed          Journal:  Aging Male        ISSN: 1368-5538            Impact factor:   5.892


  3 in total

1.  A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy.

Authors:  Nicholas P Whitehead; Min Jeong Kim; Kenneth L Bible; Marvin E Adams; Stanley C Froehner
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-28       Impact factor: 11.205

Review 2.  Gas what: NO is not the only answer to sexual function.

Authors:  G Yetik-Anacak; R Sorrentino; A E Linder; N Murat
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

3.  Simvastatin offers new prospects for the treatment of Duchenne muscular dystrophy.

Authors:  Nicholas P Whitehead; Min Jeong Kim; Kenneth L Bible; Marvin E Adams; Stanley C Froehner
Journal:  Rare Dis       Date:  2016-04-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.